Banque Cantonale Vaudoise Raises Stake in Illumina, Inc. $ILMN

Banque Cantonale Vaudoise boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 447.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,964 shares of the life sciences company’s stock after buying an additional 5,693 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Illumina were worth $661,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in ILMN. Empowered Funds LLC increased its holdings in Illumina by 113.7% during the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock worth $737,000 after purchasing an additional 4,940 shares during the period. Sivia Capital Partners LLC purchased a new stake in shares of Illumina in the 2nd quarter worth $621,000. Parkside Financial Bank & Trust grew its position in shares of Illumina by 65.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after buying an additional 115 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Illumina by 12.6% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 138,171 shares of the life sciences company’s stock worth $13,183,000 after buying an additional 15,456 shares in the last quarter. Finally, Allworth Financial LP increased its stake in shares of Illumina by 7.3% during the second quarter. Allworth Financial LP now owns 6,307 shares of the life sciences company’s stock valued at $602,000 after buying an additional 430 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Barclays increased their target price on shares of Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a report on Monday, December 15th. TD Cowen reaffirmed a “hold” rating on shares of Illumina in a research report on Wednesday, January 7th. UBS Group reiterated a “neutral” rating and set a $135.00 price objective on shares of Illumina in a research note on Friday, February 6th. Guggenheim lifted their price objective on shares of Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a report on Monday, January 26th. Finally, Wall Street Zen raised shares of Illumina from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 14th. Six research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Illumina currently has a consensus rating of “Hold” and an average target price of $129.69.

Illumina Trading Down 4.9%

NASDAQ:ILMN opened at $115.56 on Friday. The stock has a market capitalization of $17.67 billion, a price-to-earnings ratio of 21.20, a PEG ratio of 2.32 and a beta of 1.45. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $155.53. The company has a quick ratio of 1.72, a current ratio of 2.08 and a debt-to-equity ratio of 0.55. The firm has a 50 day moving average of $133.45 and a 200 day moving average of $119.68.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.26 by $0.09. The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.95 EPS. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, sell-side analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Patricia Leckman sold 2,370 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the transaction, the senior vice president directly owned 16,321 shares of the company’s stock, valued at $1,896,173.78. This trade represents a 12.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.60% of the stock is currently owned by company insiders.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.